Many agents targeting IL-8 and IL-8 receptors, and many combined strategies are under clinical investigation: monoclonal antibodies, neutralizing antibodies, direct antagonists, antibodies anti-CXCR1 and -CXCR2, in different tumor types, with the aim of increasing the anti-tumoral efficacy [64, 65]. This evidence concerns the gene CXCR2 and neoplasm.